Researchers find model system to study promising cancer drug

Researchers have found that the budding yeast (Saccharomyces cerevisiae) is an acceptable model system to study KP1019, an anti-cancer drug that uses ruthenium, a rare metal, a new study found. Researchers had previously been interested in studying KP1019 because it is believed to cause cancer cell death and is not known to have negative secondary side effects for healthy tissues.

"We wanted to learn more about how KP1019 works on a cellular level, and how the drug acts on can be indicative of how it will perform on ," said Pamela Hanson, associate professor of biology at Birmingham-Southern College in Alabama. "Besides the economic advantages, there are good scientific reasons to work with yeast, including the abundance of yeast genetic and genomic tools."

In past research, KP1019 has been shown to inhibit ovarian tumor cell production, cause death of and reduce overall tumor size.

Along with testing the hypothesis that yeast could be a good model system for studying KP1019, researchers wanted to identify how the drug was internalized by cells. KP1019 was taken up within two hours and caused a dose-dependent increase in cell death. It was also found to delay within one hour, most likely the result of KP1019 binding to and damaging DNA.

"More research needs to be done on how KP1019 is internalized," said Hanson. "We suspect that the drug enters cells through more than one route."

Previous studies showed that this drug entered cancer cells, at least in part, through the transferrin-mediated iron-uptake pathway; however, yeast does not contain this specific pathway. Therefore, there must be other means for this drug to enter cells.

More information: The findings will appear in the January edition of the journal Molecular Pharmacology. KP1019 is currently in clinical trials.

add to favorites email to friend print save as pdf

Related Stories

Overcoming cancer drug resistance with nanoparticles

Jan 20, 2012

One of the ways in which cancer cells evade anticancer therapy is by producing a protein that pumps drugs out of the cell before these compounds can exert their cell-killing effects. A research team at Northwestern University ...

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments